Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Document › Details

Horizon Discovery Group plc. (5/26/17). "Press Release: Horizon Discovery Introduces Four BRAF Resistant Melanoma PDX Models". Cambridge, UK.

Organisations Organisation Horizon Discovery Group plc (LSE: HZD)
  Group Horizon Discovery (Group)
  Organisation 2 Wistar Institute, The
Products Product Patient-Derived Xenograft model (PDX model)
  Product 2 oncology
Index term Index term Horizon Discovery–Wistar Institute: animal model, 201607– license excl to 153 of Wistar’s melanoma PDX models
Person Person Odgaard, Katie (Zyme Communications 201108 Senior Account Manager before College Hill Life Sciences)

> PDX models of tumors offer better in vivo insights for cancer research and drug development

> Highly characterized models, originally exclusively licensed from The Wistar Insitute

Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world leader in the application of gene editing technologies, today announced it has added four BRAF-resistant melanoma PDX (patient derived xenograft) models to its range of commercially available in vivo models to support drug efficacy studies.

PDX models are created by implanting cancerous tissue from a human primary tumor directly into immunodeficient mouse or rat models, enabling acceleration of oncology research or drug discovery and development programs. PDX models may be used to support studies including preclinical drug screening, preclinical combination therapeutics screening, or identification and analysis of biomarkers. The BRAF-resistant melanoma models available from Horizon have been highly characterized, including comprehensive patient histories, sequencing analysis data, and protein expression data.

The complex mix of genetics between individuals and even within a single tumor in cancer is an enormous challenge for cancer research and drug development, which can be further complicated when the impact of the tumour microenvironment is considered. This is where it can be helpful to examine a PDX model of tumors for better in vivo insights. The four models now available from Horizon have been proven to be highly valuable for work on BRAF therapy resistant primary and metastatic tumors.

Dr. Chris Eden, Product Manager, Horizon Discovery, commented: “It is becoming increasingly apparent that individual genetics can have a powerful impact on the efficacy and toxicology of therapeutics. By understanding which genes and genotypes can impact a drug, not only can the right drug be directed to the right patient at the right dose, but more efficient clinical trials can be designed, offering the promise of less costly, faster, and lower risk trials for pharmaceutical partners.”

Horizon’s has partnered with The Wistar Institute of Anatomy and Biology in Philadelphia, Pennsylvania to make available their large collection of highly characterized Melanoma PDX models to the research community. These melanoma models are representative of all previously well-described melanoma subtypes identified by the Cancer Genome Atlas (TCGA).

More information on Horizon Discovery’s range of PDX models can be found here:


Media contact:

For further information from Horizon Discovery Group plc, please contact:
Zyme Communications (Trade and Regional Media)
Katie Odgaard
Tel: +44 (0)7787 502 947

About Horizon Discovery Group plc

Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health.

Horizon’s core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter almost any gene sequence in human or mammalian cell-lines.

Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and animal models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizon’s commercial offering has been adopted by over 1,600 unique research organizations in over 50 countries as well as in the Company’s own R&D pipeline to support a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalized basis.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”.

Record changed: 2017-05-31


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Horizon Discovery (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px

» top